Other medicines were associated with differing cancer immunotherapy outcomes
A meta-analysis linked antibiotics and proton pump inhibitors with poorer outcomes and probiotics with favorable signals, but the abstract cannot establish causes or treatment benefits.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review reported poorer survival and tumor-response outcomes associated with antibiotic or proton pump inhibitor use around cancer immunotherapy. Probiotic exposure showed favorable signals. The abstract provides no numerical effect estimates or study-design breakdown, so these associations cannot show that changing these products would improve outcomes or that gut-microbiome changes caused the differences.
The abstract omits effect estimates, confidence intervals and the designs of included studies. Its broad microbiome framing does not establish that microbiome changes explain the reported clinical associations.
What researchers found
Overall survival, progression-free survival and tumor response
Antibiotic exposure within 3 months before or after immunotherapy began versus no antibiotics; outcome follow-up lengths and effect sizes are not reported.
Several clinical endpoints
The review examined overall survival, time without cancer progression and objective tumor response. These are different clinical endpoints, and the abstract does not quantify the association for any of them.
Exposure needs context
The authors examined medicine timing and treatment settings as well as cancer type. The reported patterns leave open whether medicine exposure, the reasons for prescribing it or other differences explain the outcomes.
The original publication
Unraveling gut microbiome interferences in cancer immunotherapy: a meta-analysis of diverse drug effects.
Xu J, Song J, Fu Z et al.
BMC Cancer · 2025
- PubMed ID
- 41250081
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.